Literature DB >> 19576532

Delirium prevention and treatment.

Yoanna Skrobik1.   

Abstract

Delirium occurs in 35% to 80% of critically ill hospitalized patients. Little is known of delirium prevention and treatment in the critical care setting. Trials emphasizing early mobilization suggest that this nonpharmacologic approach is associated with improved outcome as well as "delirium days". Titration and reduction of opiate analgesics and sedatives may improve subsyndromal delirium rates. All critical care caregivers should rigorously screen for alcohol abuse, apply alcohol withdrawal scales in alcoholic patients, and titrate sedative drugs. No nonpharmacologic approach or drug has been shown to be beneficial once delirium is established. Considering the importance and the consequences of delirium in the critical care setting, addiction studies are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576532     DOI: 10.1016/j.ccc.2009.05.003

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  10 in total

1.  Preoperative Risk Factors for Subsyndromal Delirium in Older Adults Who Undergo Joint Replacement Surgery.

Authors:  Dawn L Denny; Glenda Lindseth
Journal:  Orthop Nurs       Date:  2017 Nov/Dec       Impact factor: 0.913

Review 2.  Delirium in older adults.

Authors:  Dennis M Popeo
Journal:  Mt Sinai J Med       Date:  2011 Jul-Aug

Review 3.  A Review of Multifaceted Care Approaches for the Prevention and Mitigation of Delirium in Intensive Care Units.

Authors:  Ashley W Collinsworth; Elisa L Priest; Claudia R Campbell; Eduard E Vasilevskis; Andrew L Masica
Journal:  J Intensive Care Med       Date:  2014-10-27       Impact factor: 3.510

4.  An analysis of patient safety incident reports describing injuries to staff working in critical care in the North West of England between 2009 and 2013.

Authors:  Antony N Thomas; Daniel Horner; Robert J Taylor
Journal:  J Intensive Care Soc       Date:  2015-03-02

5.  Prophylactic melatonin for delirium in intensive care (Pro-MEDIC): a randomized controlled trial.

Authors:  Bradley Wibrow; F Eduardo Martinez; Erina Myers; Andrew Chapman; Edward Litton; Kwok M Ho; Adrian Regli; David Hawkins; Andrew Ford; Frank M P van Haren; Simon Wyer; Joe McCaffrey; Alan Rashid; Erin Kelty; Kevin Murray; Matthew Anstey
Journal:  Intensive Care Med       Date:  2022-02-27       Impact factor: 17.440

6.  Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study.

Authors:  John W Devlin; Yoanna Skrobik; Richard R Riker; Eric Hinderleider; Russel J Roberts; Jeffrey J Fong; Robin Ruthazer; Nicholas S Hill; Erik Garpestad
Journal:  Crit Care       Date:  2011-09-17       Impact factor: 9.097

7.  Prophylactic Melatonin for Delirium in Intensive Care (Pro-MEDIC): study protocol for a randomised controlled trial.

Authors:  F Eduardo Martinez; Matthew Anstey; Andrew Ford; Brigit Roberts; Miranda Hardie; Robert Palmer; Lynn Choo; David Hillman; Michael Hensley; Erin Kelty; Kevin Murray; Bhajan Singh; Bradley Wibrow
Journal:  Trials       Date:  2017-01-06       Impact factor: 2.279

8.  Statistical analysis plan for the Prophylactic Melatonin for Delirium in Intensive Care (ProMEDIC): a randomised controlled trial.

Authors:  Bradley Wibrow; F Eduardo Martinez; Andrew Ford; Erin Kelty; Kevin Murray; Kwok M Ho; Edward Litton; Erina Myers; Matthew Anstey
Journal:  Trials       Date:  2021-01-05       Impact factor: 2.279

Review 9.  Preventive Intervention to Prevent Delirium in Patients Hospitalized in Intensive Care Unit.

Authors:  Padideh Ghaeli; Fatemeh Shahhatami; Mojtaba Mojtahed Zade; Mostafa Mohammadi; Mohammad Arbabi
Journal:  Iran J Psychiatry       Date:  2018-04

10.  Efficacy of Low-Dose Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Youlim Kim; Hyung-Sook Kim; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Sang-Min Lee; Jae Ho Lee; Choon-Taek Lee; Yeon Joo Lee
Journal:  J Clin Med       Date:  2019-12-27       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.